New clinical trial data from China suggest that hydroxychloroquine may not be a useful treatment for COVID-19 patients.
The study of 150 hospitalized COVID-19 patients found that adding the antimalarial drug did not improve upon the standard-of-care.
The malaria drug did appear to reduce inflammation, but more adverse events were observed in the hydroxychloroquine group vs. the standard-of-care cohort.
Sanford Health, a rural nonprofit health care system in South Dakota, announced Monday that it is leading a trial of hydroxychloroquine in 2,000 outpatients exposed to COVID-19 (DID, April 14).
Access details of the China study here: bit.ly/2xAaMIb. — Jordan Williams